Metabolic syndrome and the use of antipsychotics

Peritogiannis, Vaios; Tsouli, Sofia; Zafiris, Spyros; Pappas, Dimitrios; Mavreas, Venetsanos

doi:10.1186/1744-859x-5-s1-s269

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drugs such as clozapine, olanzapine, quetiapine and a combination of clozapine and quetiapine have been found to be associated with new‐onset diabetes. According to Peritogiannis et al . (2006), olanzapine is the compound associated with greater incidence of weight gain, abnormalities in glucose–insulin homeostasis and lipid metabolism.…”

Section: Introductionmentioning

confidence: 99%

Weight gain and lipid–glucose profiles among patients taking antipsychotic medications: comparisons for prescriptions administered using algorithms versus usual care

Koch

Scott

2011

Psychiatric Ment Health Nurs

View full text Add to dashboard Cite

The purpose of this study was to determine if treatment strategy had a significant effect on the occurrence of physiological changes consistent with metabolic syndrome and/or type 2 diabetes in patients using atypical antipsychotic medications. The four variables assessed were: weight gain, fasting blood sugar, triglycerides and cholesterol. The two strategies compared were (1) evidence-based practice, derived from the Texas Medication Algorithm Project, and (2) practitioner preference. A retrospective chart review was performed on patients diagnosed with a chronic psychiatric disorder being treated with atypical antipsychotics. The dates of the reviewed records were from 1 January 2008 to 31 December 2008. The sample of patients totaled 113. Statistical analysis included logistic regression for each of the four variables assessed. The use of evidence-based practice guidelines was found to have strong positive effects on two of the four variables assessed. Further studies need to be conducted to include medications being taken to lower lipids and blood sugar. Overall, the use of evidence-based practice guidelines has a positive effect on weight, triglycerides and cholesterol. It is important that patients be closely monitored and changes made in a timely manner to minimize adverse effects of atypical antipsychotics.

show abstract

Section: Introductionmentioning

confidence: 99%

Weight gain and lipid–glucose profiles among patients taking antipsychotic medications: comparisons for prescriptions administered using algorithms versus usual care

Koch

Scott

2011

Psychiatric Ment Health Nurs

View full text Add to dashboard Cite

show abstract

Olanzapine Long-Acting Injection

Frampton

2010

Drugs

View full text Add to dashboard Cite

Olanzapine pamoate (olanzapine long-acting injection [OLAI]; Zypadhera®; Zyprexa® Relprevv™) is the intramuscular depot formulation of the atypical antipsychotic olanzapine. In two pivotal, double-blind clinical trials of 8 or 24 weeks' duration, the efficacy of recommended dosages of OLAI injected every 2 or 4 weeks (without oral supplementation) was greater than that of placebo in improving symptoms in acutely ill patients with schizophrenia, and generally similar to that of continuing oral olanzapine in preventing psychotic exacerbations in patients with schizophrenia whose symptoms had previously been stabilized on oral olanzapine. The effectiveness of OLAI in the maintenance treatment of schizophrenia was also demonstrated in an (ongoing) open-label extension study in which the all-cause discontinuation rate was 34.3% after 18 months. OLAI is generally well tolerated. It has an adverse event profile similar to that of oral olanzapine, with the exception of adverse events related to the intramuscular route of administration; these include a manageable post-injection syndrome, which occurred in <0.1% of injections in clinical trials. The possibility of a post-injection syndrome event requires a risk management plan (RMP) to be adopted that includes observation by appropriately qualified personnel in a healthcare facility for at least 3 hours post-injection. With its potential to improve adherence to medication, and thereby treatment outcomes, OLAI is a useful addition to the pharmacological options available for the maintenance therapy of schizophrenia. Given its benefit/risk profile, OLAI appears most suited for patients who, despite responding well to oral olanzapine, have difficulties remaining adherent to this form of medication, provided they can comply with the conditions of the RMP.

show abstract

Metabolic syndrome and the use of antipsychotics

Cited by 2 publications

References 4 publications

Weight gain and lipid–glucose profiles among patients taking antipsychotic medications: comparisons for prescriptions administered using algorithms versus usual care

Weight gain and lipid–glucose profiles among patients taking antipsychotic medications: comparisons for prescriptions administered using algorithms versus usual care

Olanzapine Long-Acting Injection

Contact Info

Product

Resources

About